Results 151 to 160 of about 635,806 (258)

Gleaning the Rocky Shore? 2500 Years of Coastal Resource Use at Red Bluff 1, GunaiKurnai Country, SE Australia

open access: yesArchaeology in Oceania, EarlyView.
ABSTRACT Shell middens in Gippsland along the eastern half of Victoria's coastline have usually been characterised as small, short‐duration camp sites with relatively low shell densities and low taxonomic diversity. Here we present new excavation results from a dense, high‐diversity site at Red Bluff near the eastern end of GunaiKurnai Country, a ...
Patrick Faulkner   +17 more
wiley   +1 more source

Challenges Faced by Nurses in Disaster Management in Palestine: A Systematic Review. [PDF]

open access: yesSAGE Open Nurs
Qtait M   +7 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi   +12 more
wiley   +1 more source

G‐CSF for Mobilizing CD34+ Cells in Individuals With SCD: A Word of Caution

open access: yes
American Journal of Hematology, EarlyView.
Akshay Sharma   +17 more
wiley   +1 more source

Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of the Phase 3, Randomized, Placebo‐Controlled SOLSTICE Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Evaluate the efficacy and safety of guselkumab, an interleukin‐23p19‐subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor inhibitor (TNFi‐IR).
Alexis Ogdie   +12 more
wiley   +1 more source

Structured AI decision-making in disaster management. [PDF]

open access: yesSci Rep
Dcruz JG   +3 more
europepmc   +1 more source

Coverage generosity of novel anti‐rheumatic drugs in Medicare Advantage and stand‐alone Part D plans

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To examine coverage of self‐administered disease‐modifying anti‐rheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022‐2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T‐cell co‐stimulatory modulator, Interleukin‐6 ...
Youngmin Kwon   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy